Zika virus can be passed from an infected woman to her fetus during pregnancy, potentially leading to birth defects such as microcephaly. Scientists at Fudan University in China, Dr. Shibo Jiang and his colleagues of New York Blood Center's Laboratory of Viral Immunology, including Dr. Lanying Du, have discovered a peptide-based drug candidate that inactivates Zika virus particles and reduces transmission of Zika virus to the fetus in pregnant mice, thus having potential to be developed for treatment and prevention of Zika virus infection in high-risk populations, particularly pregnant women. 

This study was published in Nature Communication on July 25, 2017.